Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chief Human Resources Ofc | April 02, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date April 02, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,348 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Sale · Disposed 6,193 · Balance 16,348 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2026 Filed Apr 2, 2026 23:43 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,193 | $74.05 | $458,613.33 |
DisclosureSEC source: 0000874015-26-000160 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,348 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 385 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 13 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,877 Underlying: Common Stock · 385 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,760 | $0.00 Strike: $40.85 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 12 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,280 Underlying: Common Stock · 3,760 shares Expires 2034-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,510 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 11 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,744 Underlying: Common Stock · 3,510 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 10 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires 2035-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,951 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 9 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 928 Underlying: Common Stock · 6,951 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 755 | $80.84 | $61,031.94 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 8 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,541 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,030 | $80.00 | $402,394.97 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 7 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,296 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.68 to $80.675 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 14,321 | $79.12 | $1,133,005.92 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 6 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,326 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.61 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 385 | $52.87 | $20,354.95 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,951 | $32.60 | $226,602.60 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,500 | $34.69 | $190,795.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,760 | $40.85 | $153,596.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,510 | $37.58 | $131,905.80 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,977 | $81.34 | $323,490.37 |
DisclosureSEC source: 0000874015-26-000077 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,541 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.33 to $81.37 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,353 | $75.95 | $634,410.35 |
DisclosureSEC source: 0000874015-26-000064 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,518 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.94 to $75.96 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 9,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000064 · edgardoc.xml · derivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,704 Underlying: Common Stock · 9,675 shares Expires not disclosed F8 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 17,377 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000064 · edgardoc.xml · derivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,029 Underlying: Common Stock · 17,377 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 25,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000064 · edgardoc.xml · derivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,800 Underlying: Common Stock · 25,800 shares Expires not disclosed F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 17,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000064 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,545 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · derivative · entry 15 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,971 Underlying: Common Stock · 25,545 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,264 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · derivative · entry 14 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,262 Underlying: Common Stock · 9,264 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,829 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · derivative · entry 13 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,254 Underlying: Common Stock · 3,829 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,460 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · derivative · entry 12 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,879 Underlying: Common Stock · 3,460 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,101 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · derivative · entry 11 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,339 Underlying: Common Stock · 2,101 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 9,264 | $84.62 | $783,919.68 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 10 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.08 to $85.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 9,264 | $52.87 | $489,787.68 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 9 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,829 | $84.62 | $324,009.98 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 8 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.08 to $85.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,829 | $37.58 | $143,893.82 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 7 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,460 | $84.62 | $292,785.20 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 6 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.08 to $85.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,460 | $32.60 | $112,796.00 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,101 | $85.36 | $179,341.36 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.10 to $85.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,101 | $32.60 | $68,492.60 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 25,545 | $85.36 | $2,180,521.20 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.10 to $85.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:08 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 25,545 | $56.78 | $1,450,445.10 |
DisclosureSEC source: 0000874015-26-000029 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,350 | $0.00 Strike: $79.67 | $0.00 |
DisclosureSEC source: 0000874015-26-000019 · edgardoc.xml · derivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 19,350 shares Expires 2036-01-01 F1 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,777 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000285 · edgardoc.xml · derivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,777 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 16,777 | $80.91 | $1,357,442.17 |
DisclosureSEC source: 0000874015-25-000285 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.66 to $81.14 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,777 | $53.77 | $902,099.29 |
DisclosureSEC source: 0000874015-25-000285 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,263 | $73.62 | $92,983.70 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · nonDerivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 2,820 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · derivative · entry 6 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,406 Underlying: Common Stock · 2,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · derivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,820 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F3 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,000 | $72.94 | $437,653.80 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,937 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.775 to $73.04 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,000 | $48.51 | $291,060.00 |
DisclosureSEC source: 0000874015-25-000260 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,234 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · derivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,083 Underlying: Common Stock · 2,234 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 928 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · derivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 928 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 928 | $32.60 | $30,252.80 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,162 | $61.02 | $192,942.71 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,009 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.0075 to $61.045 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,234 | $37.58 | $83,953.72 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.